During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

For the first time, researchers have directly observed dopamine release in the human brain during moments of cognitive ...

Theranocure Co. Ltd. has prepared and tested new vanillic acid derivatives targeting the dopamine D1 receptor (D1R) reported to be useful for the treatment of neuroinflammation and Alzheimer’s disease ...

But in the 1970s, the discovery of dopamine receptors in the brain led to an important realization: haloperidol binds to and ...

One of the main treatments for movement disorders is a group of drugs called dopamine-receptor agonists, which include cabergoline, ropinirole, bromocriptine and pramipexole. Dopamine-receptor ...

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor antagonist for patients with Tourette syndrome. Emalex Biosciences announced ...

For the first time, scientists have confirmed a neurobiochemical link between dopamine and cognitive flexibility, according ...

"Renal-dose" dopamine is widely used in clinical practice despite the controversial benefit in the prophylaxis and treatment of acute renal failure. Goldberg et al. [1] were the first to ...

"Our results indicate that loss of BBS-1 in worm dopamine neurons results in excess ... carry the proper number and kinds of ...